SCHEMBL7715738

SCHEMBL7715738

Cc1cc(Oc2ccc(C(=O)N[C@@H](C)C(=O)O)cc2)ccc1N(CCCl)CCCl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.44
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
UTS2R Q9UKP6 1/20 0.39
CA2 P00918 3/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
EGFR P00533 1/20 0.38
ERBB2 P04626 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
MMP2 P08253 2/20 0.37
MMP9 P14780 2/20 0.37
MMP12 P39900 2/20 0.37
HRH3 Q9Y5N1 1/20 0.36
MCHR1 Q99705 1/20 0.36
MCL1 Q07820 1/20 0.36
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8722107 0.88 PYGL (0.36) CA1CA12CA9UTS2RCA2
SCHEMBL8722146 0.88 CA1 (0.43) CA1CA12CA9UTS2RCA2
SCHEMBL7717390 0.87 MAPT (0.36) CA1CA12CA9UTS2RALDH1A1
SCHEMBL8722150 0.87 CA2 (0.42) UTS2RCA2ALDH1A1SMN1; SMN2LMNA
SCHEMBL8722086 0.86 CA2 (0.42) CA1CA12CA9CA2
SCHEMBL8726548 0.86 ALDH1A1 (0.43) CA1CA12CA9UTS2RCA2
SCHEMBL7715732 0.84 EGFR (0.53) CA1CA12CA9UTS2RCA2
SCHEMBL8724202 0.83 EGFR (0.43) CA1CA12CA9UTS2RCA2
SCHEMBL7711928 0.83 MCL1 (0.43) CA1CA2MCL1
SCHEMBL8726236 0.81 TAS1R3 (0.40) ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0844885-A2 CHEMICAL COMPOUNDS ZENECA LIMITED (GB) 1998-06-03 EP claimed
WO-1997007769-A2 CHEMICAL COMPOUNDS ZENECA LIMITED (GB) 1997-03-06 WO claimed
US-6436691-B1 CONJUGATE WHICH IS SUBSTANTIALLY NON-IMMUNOGENIC IN HUMANS COMPRISING TARGETING MOIETY CAPABLE OF BINDING WITH TUMOR ASSOCIATED ANTIGEN LINKED TO MUTATED FORM OF CARBOXYPEPTIDASE B ENZYME CAPABLE OF CONVERTING PRODRUG INTO ANTICANCER DRUG ZENECA LIMITED (GB) 2002-08-20 US disclosed
WO-1998035982-A1 COMPOUNDS FOR USE IN ADEPT ZENECA LIMITED (GB) 1998-08-20 WO disclosed
EP-0844885-A2 CHEMICAL COMPOUNDS ZENECA LIMITED (GB) 1998-06-03 EP disclosed
WO-1997007769-A2 CHEMICAL COMPOUNDS ZENECA LIMITED (GB) 1997-03-06 WO disclosed